JP2013543855A5 - - Google Patents

Download PDF

Info

Publication number
JP2013543855A5
JP2013543855A5 JP2013538208A JP2013538208A JP2013543855A5 JP 2013543855 A5 JP2013543855 A5 JP 2013543855A5 JP 2013538208 A JP2013538208 A JP 2013538208A JP 2013538208 A JP2013538208 A JP 2013538208A JP 2013543855 A5 JP2013543855 A5 JP 2013543855A5
Authority
JP
Japan
Prior art keywords
antigen
tumor
mhc
complex
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013538208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543855A (ja
JP5991979B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/069931 external-priority patent/WO2012062904A2/en
Publication of JP2013543855A publication Critical patent/JP2013543855A/ja
Publication of JP2013543855A5 publication Critical patent/JP2013543855A5/ja
Application granted granted Critical
Publication of JP5991979B2 publication Critical patent/JP5991979B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013538208A 2010-11-12 2011-11-11 癌の予防および治療のための組成物および方法 Expired - Fee Related JP5991979B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41333010P 2010-11-12 2010-11-12
US61/413,330 2010-11-12
PCT/EP2011/069931 WO2012062904A2 (en) 2010-11-12 2011-11-11 Compositions and methods for the prevention and treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016159414A Division JP2017014255A (ja) 2010-11-12 2016-08-16 癌の予防および治療のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2013543855A JP2013543855A (ja) 2013-12-09
JP2013543855A5 true JP2013543855A5 (enExample) 2014-12-25
JP5991979B2 JP5991979B2 (ja) 2016-09-14

Family

ID=44983530

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013538208A Expired - Fee Related JP5991979B2 (ja) 2010-11-12 2011-11-11 癌の予防および治療のための組成物および方法
JP2016159414A Pending JP2017014255A (ja) 2010-11-12 2016-08-16 癌の予防および治療のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016159414A Pending JP2017014255A (ja) 2010-11-12 2016-08-16 癌の予防および治療のための組成物および方法

Country Status (14)

Country Link
US (3) US9511151B2 (enExample)
EP (1) EP2637700A2 (enExample)
JP (2) JP5991979B2 (enExample)
KR (1) KR20140037789A (enExample)
CN (2) CN105770906A (enExample)
AU (2) AU2011328077A1 (enExample)
BR (1) BR112013007064A2 (enExample)
CA (1) CA2817710C (enExample)
IL (1) IL225471B (enExample)
MX (1) MX350203B (enExample)
NZ (1) NZ608695A (enExample)
RU (2) RU2623038C2 (enExample)
SG (2) SG189909A1 (enExample)
WO (1) WO2012062904A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140105980A1 (en) * 2012-10-11 2014-04-17 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
CN101678090B (zh) * 2007-03-07 2012-04-11 乌第有限合伙公司 用于预防和治疗自身免疫病的组合物和方法
CN105497883A (zh) * 2010-09-29 2016-04-20 乌第有限合伙公司 使用生物相容性的生物可吸收纳米球治疗自身免疫病的方法
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
CA2869786A1 (en) * 2012-06-08 2013-12-12 Alkermes, Inc. Fusion polypeptides comprising mucin-domain polypeptide linkers
EP2711418B1 (en) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
WO2014052545A2 (en) * 2012-09-28 2014-04-03 Dana-Farber Cancer Institute, Inc. Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
KR102453188B1 (ko) 2013-06-24 2022-10-07 넥스이뮨, 인크. 면역요법을 위한 조성물 및 방법
ES2612918T3 (es) 2013-07-10 2017-05-19 Miltenyi Biotec Gmbh Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles
SG11201603487YA (en) 2013-11-04 2016-05-30 Uti Limited Partnership Methods and compositions for sustained immunotherapy
TWI689310B (zh) 2014-07-11 2020-04-01 巨生生醫股份有限公司 治療鐵缺乏症之方法
CN107698664A (zh) * 2014-09-05 2018-02-16 马恒标 大蒜中提取得到的抗肿瘤活性的多肽
IL293714A (en) 2014-10-20 2022-08-01 Juno Therapeutics Inc Methods and compositions for dosing in adoptive cell therapy
KR102825102B1 (ko) 2014-12-24 2025-06-26 넥스이뮨, 인크. 면역요법을 위한 나노입자 조성물 및 방법
WO2016198932A2 (en) * 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy
JP2018518689A (ja) * 2015-05-14 2018-07-12 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイThe Board Of Trustees Of The University Of Illinois バイオマーカーとして循環腫瘍細胞を使用するがん治療の有効性をモニタリングするための方法
EP3303635B1 (en) 2015-06-01 2021-09-01 California Institute of Technology Compositions and methods for screening t cells with antigens for specific populations
CN110191893B (zh) * 2016-11-22 2023-03-21 武汉华大吉诺因生物科技有限公司 多肽及其应用
ES2988795T3 (es) 2017-02-27 2024-11-21 Juno Therapeutics Inc Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular
US12258613B2 (en) 2017-03-08 2025-03-25 California Institute Of Technology Pairing antigen specificity of a T cell with T cell receptor sequences
AU2018248961B2 (en) 2017-04-07 2024-06-20 Uti Limited Partnership Assay to measure the potency of receptor-ligand interactions in nanomedicines
CN110996974A (zh) * 2017-06-16 2020-04-10 梅约医学教育与研究基金会 增加免疫应答的材料和方法
TWI832820B (zh) * 2017-07-21 2024-02-21 美商伯克利之光生命科技公司 抗原呈現合成表面、共價功能化表面、經活化之t細胞及其用途
SG11202003688PA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Process for generating therapeutic compositions of engineered cells
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
US12397038B2 (en) 2017-11-29 2025-08-26 Uti Limited Partnership Ubiquitous antigens for treatment of autoimmune or inflammatory diseases
CA3084446A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
CN108359013A (zh) * 2018-02-07 2018-08-03 上海交通大学 一种人工抗原递呈纳米制剂及其用于体内外扩增特异性t细胞的应用
JP2022502017A (ja) 2018-09-21 2022-01-11 バークレー ライツ,インコーポレイテッド 官能基化ウェルプレート、その作製及び使用方法
CN114341175A (zh) * 2019-05-23 2022-04-12 乌第有限合伙公司 包含非经典mhc的纳米颗粒及其用途
US20220249389A1 (en) 2019-07-12 2022-08-11 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
MX2019015508A (es) 2019-12-18 2021-06-21 Univ Guadalajara Nanopartículas para el tratamiento del cáncer.
CN117440972A (zh) 2021-03-24 2024-01-23 奥克梅斯公司 Upar抗体和具有所述抗体的融合蛋白
CN113403276A (zh) * 2021-06-23 2021-09-17 河北大学 抗体功能化的外泌体制剂及其制备方法和应用
WO2024130393A1 (en) * 2022-12-21 2024-06-27 Moskovchenko Svitlana Nanoparticle and method of synthesis thereof

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000470A (en) 1908-02-11 1911-08-15 Frank C Widmann Ring-mold.
US1017295A (en) 1910-08-20 1912-02-13 Adolph F Hensler Journal-box.
US1048588A (en) 1911-05-05 1912-12-31 Adams & Westlake Co Pole-changer.
US1008080A (en) 1911-07-15 1911-11-07 Jacub Schwartzman Bed-spring.
US1012404A (en) 1911-07-29 1911-12-19 Frederick L S Means Protective caster.
US1044155A (en) 1912-04-11 1912-11-12 Diamond Match Co Splint-drying means for match-machines.
US4367110A (en) 1979-07-02 1983-01-04 Toppan Printing Co. Decorative laminate and a manufacturing method therefor
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4478946A (en) 1981-07-02 1984-10-23 South African Inventions Development Corporation Carrier bound immunosorbent
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0092227B1 (en) 1982-04-19 1988-07-27 Nissan Motor Co., Ltd. Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US5171582A (en) 1985-07-31 1992-12-15 Ghent William R Treatment of iodine deficiency diseases
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5260422A (en) 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US6106840A (en) 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US4859839A (en) 1988-07-08 1989-08-22 Counter Computer Corporation Point-of-sale terminal for laundry or dry cleaning establishments
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
DE69232875T2 (de) 1991-04-23 2003-08-21 Anergen, Inc. MHC-Konjugate zur Verbesserung der Autoimmunität.
US5200189A (en) 1991-07-23 1993-04-06 Ecolab Inc. Peroxyacid antimicrobial composition
CA2130997A1 (en) 1992-02-27 1993-09-02 C. Garrison Fathman Early antigen for autoimmune diabetes
JP2631436B2 (ja) 1992-07-24 1997-07-16 徳厚 小島 排水立て管継手
US5972336A (en) 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
AU2076895A (en) 1994-03-28 1995-10-17 Daiichi Pharmaceutical Co., Ltd. Liposomes
US6103379A (en) 1994-10-06 2000-08-15 Bar-Ilan University Process for the preparation of microspheres and microspheres made thereby
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
DE19508058A1 (de) 1995-02-21 1996-08-22 Schering Ag Verfahren zur Herstellung von DTPA-Tetraestern der terminalen Carbonsäuren und deren Verwendung zur Herstellung pharmazeutischer Mittel
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
DE69730038T2 (de) 1996-08-16 2004-11-25 The President And Fellows Of Harvard College, Cambridge Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
PT1017721E (pt) 1997-09-16 2009-05-07 Univ Oregon Health & Science Moléculas de mhc recombinantes úteis para manipulação de células t específicas do antigénio
CA2321262A1 (en) 1998-02-19 1999-08-26 President And Fellows Of Harvard College Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor
WO1999056763A1 (en) 1998-05-07 1999-11-11 The Regents Of The University Of California Use of neglected target tissue antigens in modulation of immune responses
DE19825371A1 (de) 1998-06-06 1999-12-09 Bayer Ag Elektrochrome Anzeigevorrichtung mit isolierten Zuleitungen
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US7807377B2 (en) * 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
US6150022A (en) 1998-12-07 2000-11-21 Flex Products, Inc. Bright metal flake based pigments
JP2000213425A (ja) 1999-01-20 2000-08-02 Hino Motors Ltd Egrク―ラ
US7090973B1 (en) 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
CN1377279A (zh) 1999-05-06 2002-10-30 遗传研究所有限公司 可溶性共同刺激分子增强免疫应答的用途
CA2386377A1 (en) 1999-10-06 2001-04-12 The Trustees Of The University Of Pennsylvania Cell targeting compositions and methods of using the same
US6585947B1 (en) 1999-10-22 2003-07-01 The Board Of Trustess Of The University Of Illinois Method for producing silicon nanoparticles
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR100379250B1 (ko) 2000-12-04 2003-04-08 한국과학기술연구원 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법
CA2440474A1 (en) 2001-04-05 2002-10-17 Virginia Mason Research Center Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment
DE10117858A1 (de) 2001-04-10 2002-10-24 Gsf Forschungszentrum Umwelt MHC-Tetramere
US20070129307A1 (en) 2001-06-22 2007-06-07 The University Of British Columbia Insulin epitopes for the treatment of type 1 diabetes
WO2003001204A2 (en) 2001-06-22 2003-01-03 The University Of British Columbia Type 1 diabetes diagnostics and therapeutics
US20030124149A1 (en) 2001-07-06 2003-07-03 Shalaby Shalaby W. Bioactive absorbable microparticles as therapeutic vaccines
ATE388691T1 (de) 2001-07-10 2008-03-15 Univ North Carolina State Träger zur freisetzung von nanopartikeln
DE10144252A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
DE60228128D1 (de) 2001-11-09 2008-09-18 Nanosphere Inc Biokonjugat-nanopartikelsonden
DK2224012T3 (da) 2001-12-17 2013-05-13 Corixa Corp Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
US6688494B2 (en) 2001-12-20 2004-02-10 Cima Nanotech, Inc. Process for the manufacture of metal nanoparticle
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
JP5068931B2 (ja) 2002-07-12 2012-11-07 ザ ジョンズ ホプキンス ユニバーシティー 独自のクローン形質のリンパ球受容体に結合する試薬および方法
DE10310261A1 (de) 2003-03-05 2004-09-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Identifizierung von Antigen-Epitopen
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US6929675B1 (en) 2003-04-24 2005-08-16 Sandia Corporation Synthesis metal nanoparticle
US20050118102A1 (en) 2003-04-28 2005-06-02 Intematix Corporation Spin resonance heating and/or imaging in medical applications
US20040224402A1 (en) 2003-05-08 2004-11-11 Xcyte Therapies, Inc. Generation and isolation of antigen-specific T cells
EP1628675A4 (en) 2003-05-20 2008-05-07 Univ Virginia ANTIGENS AS A GOAL FOR PREVALENT PATHOGENIC T CELLS IN TYP-1 DIABETES AND USES THEREOF
US7060121B2 (en) 2003-06-25 2006-06-13 Hsing Kuang Lin Method of producing gold nanoparticle
WO2005007673A2 (en) 2003-07-03 2005-01-27 Rush University Medical Center Immunogenic peptides
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
GB0321937D0 (en) 2003-09-19 2003-10-22 Univ Liverpool Nanoparticle conjugates and method of production thereof
WO2005036035A2 (en) 2003-10-09 2005-04-21 Emerson Electric Co. Valve assembly
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US9079765B2 (en) 2004-10-01 2015-07-14 Midatech Ltd. Nanoparticles comprising antigens and adjuvants, and immunogenic structures
WO2006054806A1 (ja) 2004-11-22 2006-05-26 Locomogene, Inc. クローン病関連自己抗原
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
US20070059775A1 (en) 2005-03-29 2007-03-15 The Trustees Of Columbia University In The City Of New York Synthesis and conjugation of iron oxide nanoparticles to antibodies for targeting specific cells using fluorescence and MR imaging techniques
US7562421B2 (en) 2005-04-03 2009-07-21 Magen Eco Energy A.C.S. Ltd. Connecting clasp
US7326399B2 (en) 2005-04-15 2008-02-05 Headwaters Technology Innovation, Llc Titanium dioxide nanoparticles and nanoparticle suspensions and methods of making the same
CN101247826A (zh) 2005-08-25 2008-08-20 大鹏药品工业株式会社 固定或内包t细胞识别抗原表位肽的生物降解性纳米粒子
EP1954252B1 (en) 2005-12-02 2016-02-03 GlaxoSmithKline Biologicals SA Nanoparticles for use in immunogenic compositions
US20100061984A1 (en) 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
AU2007283731B2 (en) 2006-08-11 2013-10-24 Katholieke Universiteit Leuven Immunogenic peptides and their use in immune disorders
US7816814B1 (en) 2006-08-18 2010-10-19 Hennessy Michael J Bi-directional power converters
MX2009007101A (es) 2006-12-29 2009-12-01 Univ Washington Superficies y materiales antibioincrustación bifuncionales.
WO2008115641A2 (en) 2007-02-15 2008-09-25 Yale University Modular nanoparticles for adaptable vaccines
US20150250871A1 (en) 2007-03-07 2015-09-10 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
US20140105980A1 (en) 2012-10-11 2014-04-17 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
CN101678090B (zh) 2007-03-07 2012-04-11 乌第有限合伙公司 用于预防和治疗自身免疫病的组合物和方法
WO2008118861A2 (en) 2007-03-23 2008-10-02 The University Of North Carolina At Chapel Hill Discrete size and shape specific organic nanoparticles designed to elicit an immune response
EP2167537A2 (en) * 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
CN202189297U (zh) 2007-07-22 2012-04-11 康代有限公司 用于控制电子电路的制造过程的系统
JP5085240B2 (ja) 2007-09-03 2012-11-28 日本電波工業株式会社 水晶デバイス及び水晶デバイスの製造方法
EP2591804A3 (en) 2007-09-24 2014-04-16 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
WO2009064273A1 (en) 2007-11-16 2009-05-22 Paul Appelbaum Apparatus and method for packaging articles in clear plastic packages
US8779088B2 (en) 2007-12-17 2014-07-15 Marfl Ab Vaccine for the treatment of Mycobacterium related disorders
US8629098B2 (en) 2008-01-15 2014-01-14 Yale University Compositions and methods for adoptive and active immunotherapy
EP2240782A2 (en) 2008-02-04 2010-10-20 Ulive Enterprises Limited Nanoparticle conjugates
JP2011525477A (ja) 2008-03-04 2011-09-22 リクイディア・テクノロジーズ・インコーポレーテッド 免疫調節剤粒子および処置方法
WO2009126835A2 (en) 2008-04-09 2009-10-15 University Of Washington Techtransfer Invention Licensing Magnetic nanoparticle and method for imaging t cells
US20090258355A1 (en) 2008-04-11 2009-10-15 Brookhaven Science Associates, Llc Nanoscale Clusters and Methods of Making Same
MX2011002250A (es) 2008-08-25 2011-08-17 Amplimmune Inc Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
WO2010037397A1 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
CA2642141A1 (en) 2008-10-20 2010-04-20 Innovative Microelectronics Inc. Flange alignment pin
CA2743590A1 (en) 2008-11-12 2010-05-20 Yeda Research And Development Co. Ltd. Diagnosis of multiple sclerosis
WO2010080032A2 (en) 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
SG173041A1 (en) 2009-01-20 2011-08-29 Univ Northwestern Compositions and methods for induction of antigen-specific tolerance
US8383085B2 (en) 2009-05-29 2013-02-26 University Of Manitoba Methods of making iron-containing nanoparticles
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
GB0922066D0 (en) 2009-12-17 2010-02-03 Univ Belfast Modulator
GB201003088D0 (en) 2010-02-24 2010-04-14 Univ Exeter Method for the preparation of a novel nanoparticle conjugate
SG10201604175XA (en) 2010-07-26 2016-07-28 Qu Biolog Inc Immunogenic anti-inflammatory compositions
PL2640711T3 (pl) 2010-08-25 2016-06-30 Davuluri Ramamohan Rao Ulepszony sposób otrzymywania rufinamidu
WO2012031258A1 (en) 2010-09-03 2012-03-08 Oregon Health & Science University Recombinant t-cell receptor ligands with covalently bound peptides
CN105497883A (zh) 2010-09-29 2016-04-20 乌第有限合伙公司 使用生物相容性的生物可吸收纳米球治疗自身免疫病的方法
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
WO2013034726A1 (en) 2011-09-07 2013-03-14 Midatech Limited Nanoparticle-peptide compositions
EP2758780A4 (en) 2011-09-22 2015-09-16 Marv Entpr Llc METHOD OF TREATING MULTIPLE SCLEROSIS
EP2591801A1 (en) 2011-11-14 2013-05-15 Universitätsklinikum Hamburg-Eppendorf Nanoparticle compositions for generation of regulatory T cells and treatment of autoimmune diseases and other chronic inflammatory conditions
US20130128138A1 (en) 2011-11-18 2013-05-23 Shenzhen China Star Optoelectronics Technolog Co., LTD. Flat Panel Display Device, Stereoscopic Display Device, Plasma Display Device
CA2858115A1 (en) 2011-12-09 2013-06-13 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US20150150996A1 (en) 2012-06-06 2015-06-04 Northwestern University Compositions and methods for antigen-specific tolerance
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2014096015A1 (en) 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins
US9335768B2 (en) 2013-09-12 2016-05-10 Lam Research Corporation Cluster mass flow devices and multi-line mass flow devices incorporating the same
SG11201603487YA (en) 2013-11-04 2016-05-30 Uti Limited Partnership Methods and compositions for sustained immunotherapy
WO2015200728A1 (en) 2014-06-25 2015-12-30 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
EP3233903B1 (en) 2014-12-19 2020-12-09 ETH Zürich Chimeric antigen receptors and methods of use
EP3067366A1 (en) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
EP4269601A3 (en) 2015-03-27 2024-01-10 President and Fellows of Harvard College Modified t cells and methods of making and using the same
WO2016198932A2 (en) 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy
MA44907A (fr) 2015-09-11 2018-07-18 Agenus Inc Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation
JP2020500015A (ja) 2016-11-09 2020-01-09 ユーティーアイ リミテッド パートナーシップ 組換えpMHCクラスII分子
AU2018248961B2 (en) 2017-04-07 2024-06-20 Uti Limited Partnership Assay to measure the potency of receptor-ligand interactions in nanomedicines
US12397038B2 (en) 2017-11-29 2025-08-26 Uti Limited Partnership Ubiquitous antigens for treatment of autoimmune or inflammatory diseases

Similar Documents

Publication Publication Date Title
JP2013543855A5 (enExample)
Yan et al. Current applications and future prospects of nanotechnology in cancer immunotherapy
Aikins et al. Engineered nanoparticles for cancer vaccination and immunotherapy
Feng et al. Immunomodulatory nanosystems
Sang et al. Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Dong et al. Biomaterials facilitating dendritic cell‐mediated cancer immunotherapy
He et al. Innovative utilization of cell membrane‐coated nanoparticles in precision cancer therapy
RU2013121571A (ru) Композиции и способы профилактики и лечения злокачественных новообразований
Ruan et al. Advanced biomaterials for cell‐specific modulation and restore of cancer immunotherapy
Wang et al. Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
Doroudian et al. Nanomedicine in lung cancer immunotherapy
Li et al. Immune cycle‐based strategies for cancer immunotherapy
Beg et al. Nanotherapeutic systems for delivering cancer vaccines: Recent advances
Liu et al. Application of injectable hydrogels in cancer immunotherapy
Gong et al. Functional nanomaterials optimized to circumvent tumor immunological tolerance
Li et al. Designing and engineering of nanocarriers for bioapplication in cancer immunotherapy
Zhang et al. The synergistic strategies for the immuno‐oncotherapy with photothermal nanoagents
Khatua et al. Advances in engineered nanosystems: immunomodulatory interactions for therapeutic applications
Li et al. Emerging nanoparticle platforms for CpG oligonucleotide delivery
Zhao et al. Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy
JP2018536002A5 (enExample)
Yin et al. Research advances in nanomedicine applied to the systemic treatment of colorectal cancer
Zhao et al. Nanotechnology-based immunotherapies to combat cancer metastasis
Kim et al. Enhancement of immune responses elicited by nanovaccines through a cross-presentation pathway
Zhu et al. Tumor immune microenvironment-modulated nanostrategy for the treatment of lung cancer metastasis